PM

Praveen Malhotra

Director Director DIN 07249414
DIN 07249414 First appointment Nov 2015 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Past companies 2 historical roles
Total affiliations 2 Since Nov 2015
Shareholding value β€’β€’β€’β€’ Premium profile

About Praveen Malhotra

Data last updated:

Praveen Malhotra was a Director at Next Gen Pharma India Private Limited (2018–2021) and Designated Partner at Allante Healthcare Llp (from 2015). The companies operate in Pharma.

DIN 07249414
Primary Designation Director
Industry Pharma
First Appointment 16 Nov 2015
Oldest Company Age 11 yrs

Previous companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director15 Jan 20182004₹5.80 Cr (FY 2023)Active
Designated Partner16 Nov 20152015Strike Off

Explore Director's current and past company associations Uncover their professional journey today!

Directorship timeline

Open interactive timeline →
Allante Healthcare Llp
Next Gen Pharma India Private Limited
Premium access

Shareholding and investment profile for Praveen Malhotra

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Praveen Malhotra

Praveen Malhotra was first appointed on 16 Nov 2015 as Designated Partner at Allante Healthcare Llp. The most recent appointment on record is 15 Jan 2018 at Next Gen Pharma India Private Limited.

Praveen Malhotra held 2 earlier board appointments: Next Gen Pharma India Private Limited (Director, 15 Jan 2018 to 28 Feb 2021); Allante Healthcare Llp (Designated Partner, from 16 Nov 2015).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available